R&D for Neglected Diseases: PDPs and Alternative IP Management/Tech Transfer Strategies For Improved Global Health





Moderator: Dr. Mervyn Turner, Chief Strategy Officer, Merck

Session Objectives

- Examine the challenges of tech transfer, FTO and IP management specific to PDPs and issues related to global health
- Identify how to achieve a well-balanced deal by addressing classical pitfalls and difficulties around IP/licensing and access to knowledge specific to PDPs
- Drugs for Neglected Diseases initiative
- Discuss innovative IP/licensing strategies adapted to both PDP's and pharma's objectives.

Panelists

10-minutes presentations:

- Carol Mimura ullet**University of Berkeley**, Asst Vice Chancellor
- Julie Cheng

iOWH, General Counsel and VP Business Development

Patrick Nef

MMV, Chief Business Officer

Jean-Pierre Paccaud


DNDi, Director Business Development

Drugs for Neglected Diseases initiative Gerald Siuta

TB Alliance, Business Development

A Fatal Imbalance...

Between 1975 and 2004:



Why the Pharma model does not seem to work for NTDs?

- No market: extreme poverty
- Not "visible" diseases
- Difficult to perform clinical trials
- Registration
- Distribution
- Post-registration studies

=> PDPs: a viable model to develop drugs for NTDs?



What are PDPs?

- Product Development Partnership:
 - = Public-Private Partnerships (PPPs) focused on *Product Development*
- Not-for-profit
- R&D-oriented
- Focused on a particular field/disease
- Financed by the public sector and philanthropic foundations



A populated landscape...



DNDi Drugs for Neglected Diseases initiative

Institute for OneWorld Health









Medicines for Malaria Venture







INTERNATIONAL PARTNERSHIP for MICROBICIDES






AERAS GLOBAL TB VACCINE FOUNDATION







How do PDPs work?



Drugs for Neglected Diseases initiative

Partnering is key for PDPs: What are the issues?

- Work around usual monetary compensations
- Secure PDPs' rights for NTDs:
 - Field and territory
 - Out-licensing

ected Diseases initiative

- Property of generated IP
- Termination rights
- Secure industry rights:
 - Limit scope of granted licenses
 - Obtain fair compensations (usually not cash...)
 - Confidentiality